L Fracaro1, F C V Frez1, B C Silva1, G E Vicentini1, S R G de Souza1, H A Martins1, D R Linden2, F A Guarnier3, J N Zanoni1. 1. Department of Morfological Sciences, Universidade Estadual de Maringá, Maringá, Brazil. 2. Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA. 3. Department of General Pathology, Universidade Estadual de Londrina, Londrina, Brazil.
Abstract
BACKGROUND: Cachexia is a significant problem in patients with cancer. The effect of cancer on interstitial cells of Cajal (ICC) and neurons of the gastrointestinal tract have not been studied previously. Although supplementation with L-glutamine 2% may have beneficial effects in cancer-related cachexia, and be protective of ICC in models of oxidative stress such as diabetes, its effects on ICC in cancer have also not been studied. METHODS: Twenty-eight male Wistar rats were divided into four groups: control (C), control supplemented with L-glutamine (CG), Walker 256 tumor (WT), and Walker 256 tumor supplemented with L-glutamine (WTG). Rats were implanted with tumor cells or injected with saline in the right flank. After 14 days, the jejunal tissues were collected and processed for immunohistochemical techniques including whole mounts and cryosections and Western blot analysis. KEY RESULTS: Tumor-bearing rats demonstrate reduced numbers of Myenteric ICC and deep muscular plexus ICC and yet increased Ano1 protein expression and enhanced ICC networks. In addition, there is more nNOS protein expressed in tumor-bearing rats compared to controls. L-glutamine treatment had a variety of effects on ICC that may be related to the disease state and the interaction of ICC and nNOS neurons. Regardless, L-glutamine reduced the size of tumors and also tumor-induced cachexia that was not due to altered food intake. CONCLUSIONS & INFERENCES: There are significant effects on ICC in the Walker 256 tumor model. Although supplementation with L-glutamine has differential and complex effects of ICC, it reduces tumor size and tumor-associated cachexia, which supports its beneficial therapeutic role in cancer.
BACKGROUND:Cachexia is a significant problem in patients with cancer. The effect of cancer on interstitial cells of Cajal (ICC) and neurons of the gastrointestinal tract have not been studied previously. Although supplementation with L-glutamine 2% may have beneficial effects in cancer-related cachexia, and be protective of ICC in models of oxidative stress such as diabetes, its effects on ICC in cancer have also not been studied. METHODS: Twenty-eight male Wistar rats were divided into four groups: control (C), control supplemented with L-glutamine (CG), Walker 256 tumor (WT), and Walker 256 tumor supplemented with L-glutamine (WTG). Rats were implanted with tumor cells or injected with saline in the right flank. After 14 days, the jejunal tissues were collected and processed for immunohistochemical techniques including whole mounts and cryosections and Western blot analysis. KEY RESULTS:Tumor-bearing rats demonstrate reduced numbers of Myenteric ICC and deep muscular plexus ICC and yet increased Ano1 protein expression and enhanced ICC networks. In addition, there is more nNOS protein expressed in tumor-bearing rats compared to controls. L-glutamine treatment had a variety of effects on ICC that may be related to the disease state and the interaction of ICC and nNOS neurons. Regardless, L-glutamine reduced the size of tumors and also tumor-induced cachexia that was not due to altered food intake. CONCLUSIONS & INFERENCES: There are significant effects on ICC in the Walker 256 tumor model. Although supplementation with L-glutamine has differential and complex effects of ICC, it reduces tumor size and tumor-associated cachexia, which supports its beneficial therapeutic role in cancer.
Authors: Flávia A Guarnier; Alessandra L Cecchini; Andréia A Suzukawa; Ana Leticia G C Maragno; Andréa N C Simão; Marcelo D Gomes; Rubens Cecchini Journal: Muscle Nerve Date: 2010-12 Impact factor: 3.217
Authors: Pedro J Gomez-Pinilla; Simon J Gibbons; Michael R Bardsley; Andrea Lorincz; Maria J Pozo; Pankaj J Pasricha; Matt Van de Rijn; Robert B West; Michael G Sarr; Michael L Kendrick; Robert R Cima; Eric J Dozois; David W Larson; Tamas Ordog; Gianrico Farrugia Journal: Am J Physiol Gastrointest Liver Physiol Date: 2009-04-16 Impact factor: 4.052
Authors: Kyoung Moo Choi; Simon J Gibbons; Tien V Nguyen; Gary J Stoltz; Matthew S Lurken; Tamas Ordog; Joseph H Szurszewski; Gianrico Farrugia Journal: Gastroenterology Date: 2008-09-11 Impact factor: 22.682
Authors: Andrea Lorincz; Doug Redelman; Viktor J Horváth; Michael R Bardsley; Hui Chen; Tamás Ordög Journal: Gastroenterology Date: 2008-01-18 Impact factor: 22.682
Authors: Geraldo E Vicentini; Luciane Fracaro; Sara R G de Souza; Heber A Martins; Flávia A Guarnier; Jacqueline N Zanoni Journal: PLoS One Date: 2016-09-16 Impact factor: 3.240
Authors: Veridiana Mota Moreira; Claudinéia Conationi da Silva Franco; Kelly Valério Prates; Rodrigo Mello Gomes; Ana Maria Praxedes de Moraes; Tatiane Aparecida Ribeiro; Isabela Peixoto Martins; Carina Previate; Audrei Pavanello; Camila Cristina Ianoni Matiusso; Douglas Lopes Almeida; Flávio Andrade Francisco; Ananda Malta; Laize Peron Tófolo; Sandra da Silva Silveira; Lucas Paulo Jacinto Saavedra; Katia Machado; Paulo Henrique Olivieri da Silva; Gabriel S Fabrício; Kesia Palma-Rigo; Helenir Medri de Souza; Flaviane de Fátima Silva; Giuliana Regina Biazi; Taís Susane Pereira; Elaine Vieira; Rosiane Aparecida Miranda; Júlio Cezar de Oliveira; Luiz Delmar da Costa Lima; Wilson Rinaldi; Maria Ida Ravanelli; Paulo Cezar de Freitas Mathias Journal: Front Physiol Date: 2018-05-08 Impact factor: 4.566